China-based Chipscreen Biosciences Co., Ltd (SHA: 688321) has reached an agreement with Zhejiang Hisun Pharmaceutical Co., Ltd (SHA: 600267) to terminate their strategic partnership, which was initially formed in December 2020 to support the launch of the hypoglycemic drug chiglitazar (Bilessglu) for type 2 diabetes in 19 provinces, including Henan, Zhejiang, and Jiangsu. Moving forward, Chipscreen will assume all promotional activities for the drug in mainland China.
Chiglitazar, an in-house developed drug, is a novel non-TZD peroxisome proliferator-activated receptor (PPAR) α/γ/δ pan-agonist designed for moderate activity. It serves as an insulin sensitizer with significant effects on type 2 diabetic patients. Globally, chiglitazar is the first PPAR pan-agonist approved for the treatment of type 2 diabetes and received its initial marketing approval as a monotherapy for type 2 diabetes in China in 2021. The drug was also included in the National Reimbursement Drug List (NRDL) in 2023.- Flcube.com
